A Study to Evaluate Safety and Pharmacokinetics of BIIB104 in Healthy Japanese and Non-Japanese Participants

Completed · Phase 1 · Has a placebo group

Conditions studied: Healthy Volunteer

In brief

The primary objective of the study is to evaluate the pharmacokinetics (PK) of BIIB104 in healthy Japanese and non-Japanese participants. The secondary objective of the study is to evaluate the safety and tolerability of multiple, oral doses of BIIB104 administered twice daily (BID) for 9 days, with an additional dose occurring in the morning on Day 10 in healthy Japanese and non-Japanese participants.

Key facts

Study ID
NCT05148481
Run by
Biogen
People needed
31
Starts
2021-11-23
Expected to finish
2022-02-12
Last updated by the study team
2023-04-18

Who can join

Age: 18 and older, up to 55. Sex: male. Healthy volunteers: accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.